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Abstract
Today, there are over 250 drugs being used to cure
over 100 different types of cancer, and one that might
prove effective for a certain type of cancer might
prove harmful or ineffective for another type. We plan
to screen a chemical library of tyrosine kinase
inhibitors to test their effects on glioma growth in a
GAL4xUAS Drosophila glioma model. We first tested
Temozolomide to establish proof of principle. Next,
we compared this to a group of Tyrosine Kinase
inhibitors. We found both enhancers (positive
regulators) that increase glioma growth, and
repressors (negative regulators) that suppress the
growth of the tumor through this screen. However,
none of the drugs caused a significant suppression
without unwanted lethality suggesting that a better
approach is to use low doses of different drugs in
combination rather than increase the dose of a single
drug- which is likely responsible for lethal effects
observed.

Objectives
1.
2.

3.
4.

Test combinatorial effects of each drug from the
chemical screen with 3mM Temozolomide [a
known effective concentration of Temozolomide]
Test the drug combinations for dose range and
target specificity. Find out if Temozolomide plus a
given drug act via the target pathways or other
downstream effectors.
Our studies in Drosophila are expected to
generate insights on possible modes of action of
validated drugs.
Validated drugs will be tested in mammalian
models (by our collaborators) for their efficacy and
specificity to identify the candidate-drugs for
further studies in clinical trials in the future.

Glioma Progression

Results
•

Discovered that most effective concentration of
Temozolomide was 3mM

How Temozolomide Impacts
Temozolomide is a DNA alkylating agent that is
being used in glioma treatment due to it leading to
apoptosis

Methodology

Future Directions
•
•
•
•

Continue chemical screen through Plate 1 (Drugs A-H).
Test for combinatorial effects with Tyrosine Kinase
Inhibitors determined in the Primary Drug Screen.
Test the drug combinations for dose range and target
specificity.
Use Western Blotting to determine Mode of Action
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